Adaptive Phage Therapeutics
Biotechnology, 22 Firstfield Rd, Gaithersburg, Maryland, 20878, United States, 11-50 Employees
Phone Number: 18*********
Who is ADAPTIVE PHAGE THERAPEUTICS
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been fixed, w...
Read More
-
Headquarters: 22 Firstfield Rd, Gaithersburg, Maryland, 20878, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ADAPTIVE PHAGE THERAPEUTICS
Adaptive Phage Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Adaptive Phage Therapeutics
Answer: Adaptive Phage Therapeutics's headquarters are located at 22 Firstfield Rd, Gaithersburg, Maryland, 20878, United States
Answer: Adaptive Phage Therapeutics's phone number is 18*********
Answer: Adaptive Phage Therapeutics's official website is https://aphage.com
Answer: Adaptive Phage Therapeutics's SIC: 8731
Answer: Adaptive Phage Therapeutics's NAICS: 541714
Answer: Adaptive Phage Therapeutics has 11-50 employees
Answer: Adaptive Phage Therapeutics is in Biotechnology
Answer: Adaptive Phage Therapeutics contact info: Phone number: 18********* Website: https://aphage.com
Answer: Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been fixed, while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APTs PhageBankTM approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBankTM phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APTs technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBankTM therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month